Inactive Instrument

Other languages Aviragen Therapeutics Inc Nasdaq

Equities

US0537611024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	Mar. 06
Vaxart, Inc. Announces Chief Executive Officer Changes	Mar. 06
Vaxart, Inc. Announces Management Appointments	Mar. 06
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	Jan. 19
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	Jan. 16
Vaxart, Inc. Announces CEO Changes	Jan. 16
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director	Jan. 16
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Dec. 21
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers	Nov. 02
Vaxart Says Topline Data From Phase 2 Challenge Study of Monovalent Norovirus Vaccine Meets 5 of 6 Endpoints	23-09-06
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate	23-09-06
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate	23-07-10
Vaxart Says Bivalent Norovirus Vaccine Candidate Meets Primary Endpoints in Phase 2 Trial	23-07-06
Sector Update: Health Care Stocks Slipping Late Wednesday	23-06-07
Top Midday Decliners	23-06-07
Sector Update: Health Care Stocks Falling Wednesday Afternoon	23-06-07
Sector Update: Health Care	23-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aviragen Therapeutics Inc Nasdaq

Equities

US0537611024

Other languages

Filters